153 related articles for article (PubMed ID: 17419138)
1. Herpes treatment may limit HIV transmission and progression.
Wilkinson E
Lancet Infect Dis; 2007 Apr; 7(4):249. PubMed ID: 17419138
[No Abstract] [Full Text] [Related]
2. Time to refocus on HSV interventions for HIV prevention?
Tanton C; Abu-Raddad LJ; Weiss HA
J Infect Dis; 2011 Dec; 204(12):1822-6. PubMed ID: 21998480
[No Abstract] [Full Text] [Related]
3. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
4. A missed point in deciphering the viral synergy between herpes simplex virus and HIV.
Lisco A; Vanpouille C; Margolis L
Lancet Infect Dis; 2009 Sep; 9(9):522-3. PubMed ID: 19695487
[No Abstract] [Full Text] [Related]
5. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
6. HSV therapy and HIV-1 reduction.
Eisenhut M
N Engl J Med; 2007 May; 356(22):2323-4; author reply 2324. PubMed ID: 17542070
[No Abstract] [Full Text] [Related]
7. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
8. Use of antiviral drugs to prevent herpesvirus transmission.
Crumpacker CS
N Engl J Med; 2004 Jan; 350(1):67-8. PubMed ID: 14702430
[No Abstract] [Full Text] [Related]
9. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
10. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
12. A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection.
Burton MJ; Penman A; Sunesara I; McGuire BM; Hook EW
Am J Med Sci; 2014 Dec; 348(6):455-9. PubMed ID: 25163019
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir to reduce transmission of genital herpes simplex virus infection.
Drew WL
J Infect Dis; 2009 Mar; 199(6):916. PubMed ID: 19239344
[No Abstract] [Full Text] [Related]
14. Acyclovir versus valacyclovir.
Rajalakshmi R; Kumari R; Thappa DM
Indian J Dermatol Venereol Leprol; 2010; 76(4):439-44. PubMed ID: 20657140
[No Abstract] [Full Text] [Related]
15. Oral valacyclovir in the treatment of acute retinal necrosis syndrome.
Aslanides IM; De Souza S; Wong DT; Giavedoni LR; Altomare F; Detorakis ET; Kymionis GD; Pallikaris IG
Retina; 2002 Jun; 22(3):352-4. PubMed ID: 12055471
[No Abstract] [Full Text] [Related]
16. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
18. Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Brown TJ; McCrary M; Tyring SK
J Am Acad Dermatol; 2002 Oct; 47(4):581-99. PubMed ID: 12271305
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir. New indication: for genital herpes, simpler administration.
Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
[TBL] [Abstract][Full Text] [Related]
20. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake AL; Roxby AC; Ongecha-Owuor F; Kiarie J; John-Stewart G; Wald A; Richardson BA; Hitti J; Overbaugh J; Emery S; Farquhar C
J Infect Dis; 2012 Feb; 205(3):366-75. PubMed ID: 22147786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]